SpliceBio names ophthalmology expert as chief medical officer
Spanish genetic medicines company SpliceBio today announced the appointment of Aniz Girach as chief medical officer (CMO).
Dr Girach is an ophthalmologist with over 25 years’ industry experience in the field of medical retina and genetic therapy for inherited retinal diseases. He has been involved in the development and approval of four drugs in ophthalmology. Dr Girach was global head of ophthalmology at Merck & Co (NYSE: MRK) and vice president, clinical development at Alcon Laboratories.
At Oxurion (formerly ThromboGenics) he was global head of ophthalmology and chief medical officer where he oversaw the development and approval of ocriplasmin (Jetrea), a first in class biologic therapy for retinal disease. Dr Girach was CMO at Nightstar Therapeutics where he led and oversaw the development of its gene therapy programs for inherited retinal diseases, prior to its acquisition by Biogen for $800 million. Prior to joining SpliceBio, he led the development of genetic therapies for inherited retinal diseases at ProQR Therapeutics as its CMO.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze